Yue Gao, MD
Vascular Surgery · Omaha, NENPI 1104263078
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,452 of the $9,024 with a category attached, or 71.5%. It is spread thinly across 27 manufacturers, the largest accounting for just 20.6%. Reporting peaked in 2024 at $2,326 and has fallen 54.1% since, to $1,068 in 2025.
Across 127 payments — averaging $71.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cook Medical LLC$2K
- Endologix LLC$2K
- W. L. Gore & Associates, Inc.$2K
- Bard Peripheral Vascular, Inc.$849
- Penumbra, Inc.$708
- Boston Scientific$347
- plus $2K from 21 others
Across 8 payments — averaging $650.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$5K
What the payments were for
- Grants$1,50417%
- Food & beverage$6,45272%
- Education$1,06812%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cook Medical LLC | 14 | $1,861 |
| Endologix LLC | 12 | $1,682 |
| W. L. Gore & Associates, Inc. | 23 | $1,579 |
| Bard Peripheral Vascular, Inc. | 11 | $849 |
| Penumbra, Inc. | 18 | $708 |
| Boston Scientific | 4 | $347 |
| Silk Road Medical, Inc. | 6 | $283 |
| Medtronic(2 entities) | 4 | $270 |
| Edwards Lifesciences | 2 | $235 |
| Stryker | 7 | $203 |
| Lemaitre Vascular, Inc. | 4 | $182 |
| Abbott | 1 | $142 |
| Cook Incorporated | 1 | $141 |
| Johnson & Johnson(2 entities) | 4 | $71 |
| Philips North America LLC | 1 | $70 |
| Cardiva Medical, Inc. | 2 | $59 |
| Polymedics Innovations Inc. | 1 | $54 |
| Smith+Nephew | 2 | $47 |
| KCI USA, Inc. | 2 | $45 |
| Angiodynamics, Inc. | 1 | $37 |
| Inari Medical, Inc. | 1 | $31 |
| Kerecis Limited | 1 | $30 |
| Asahi Intecc USA, Inc. | 1 | $26 |
| Abiomed | 1 | $26 |
| Tactile Systems Technology Inc | 1 | $18 |
| Innovation Technologies Inc | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EXCLUDER AAA Endoprosthesis$689
- ENDOCROSS Device$505
- Torus Stent Graft System$505
- Pristine$420
- Indigo System$237
- AngioJet Ultra 5000A$180
- GORE TAG Conformable Thoracic Endoprosthesis$179
- RotarexS 6 F x 135 cm$163
- Penumbra System$158
- Lutonix Drug Coated Balloon$157
- JETi Peripheral Catheter$142
- ENROUTE Transcarotid Neuroprotection System$140
- ENROUTE Transcarotid Stent$140
- Alto Abdominal Stent Graft System$138
- AFX2 Bifurcated Endograft System$128
- Vascular Graft$125
- RESTOREFLO$116
- ELUVIA$112
- Zenith$107
- Zilver PTX$103
How this compares
$9,024 in reported general payments places this provider in the 70th percentile of 35 vascular surgery providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 41 | $24,285 |
| EliquisApixaban | 15 | $11,450 |
| ClopidogrelClopidogrel Bisulfate | 240 | $2,368 |
| Atorvastatin Calcium | 101 | $708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $71 | $24,28541 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 35 vascular surgery providers in Nebraska.
Other vascular surgery in Omaha
- John ParkOmaha$508K
- David VogelOmaha$41K
- Marcus BaltersOmaha$27K
- Anjan TalukdarOmaha$25K
- Iraklis PipinosOmaha$24K
- Rao GuttaOmaha$21K
- Tammy RamosOmaha$10K
- Jason CookOmaha$7K
- Katherine BrownOmaha$6K
- Jonathan ThompsonOmaha$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.